Recordati Recotuss Sedative 6.5mg Symptomatic Cough Treatment 30 Chewable Tablets
- Brand: RECORDATI SpA
- Product Code: 025273083
- EAN:
- Availability: In Stock (evaso in 24 ore)
- 3 items
for 8,36€ each - 4 items
for 8,19€ each - 5 items
for 8,02€ each
Recordati
Recotuss Sedative 6.5mg
Symptomatic Cough Treatment; 30 Chewable Tablets
Active principles
Chewable tablets Each chewable tablet contains 6.5 mg dextromethorphan hydrobromide (corresponding to 5.007 mg dextromethorphan) Excipients with known effects: Sucrose
Excipients
Chewable tablets Sucrose Precipitated silica Sodium stearate Gum arabic Balsamic aroma
Therapeutic indications
Symptomatic treatment of cough.
Contraindications
Hypersensitivity to the active substance or to other chemically related substances, or to any of the excipients listed in section 6.1. Do not administer during or in the two weeks following antidepressant therapy.
Dosage
Chewable tablets Adults: dissolve two tablets in the mouth, three to four times a day. Do not exceed the recommended dose. Pediatric population Chewable tablets Children over two years of age: dissolve one tablet in the mouth three to four times a day.
Warnings and Precautions
After 5–7 days of treatment without appreciable results, consult your doctor. Dextromethorphan should be used with caution in debilitated patients. The product is not recommended in asthmatic patients. Pediatric population In children under two years of age, the preparation must be administered only in case of real need and under the direct supervision of the physician Recotuss Sedativo contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose malabsorption - galactose, or sucrase isomaltase insufficiency, should not take this medicine.
Interactions
The use of alcohol during therapy is not recommended.
Side effects
Drowsiness, gastrointestinal disturbances (nausea, vomiting), dizziness may occur during therapy. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/it/responsabili.
Pregnancy and breastfeeding
In pregnant women, the preparation must be administered only in case of real need and under the direct supervision of the doctor.